Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
about
Onto better TRAILs for cancer treatmentTargeting the apoptosis pathway in hematologic malignanciesA series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potencyCaspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcomaGene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesWnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodiesTargeting a novel N-terminal epitope of death receptor 5 triggers tumor cell death.Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway.Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody.Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formationDrozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response.Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival.Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes.Functional imaging of legumain in cancer using a new quenched activity-based probeFractional killing arises from cell-to-cell variability in overcoming a caspase activity thresholdActivating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma.Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA.Molecular targeted approaches for treatment of pancreatic cancer.Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse ModelsWithanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation.The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and AxlCells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes.TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistancePancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5.Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicinTo kill a tumor cell: the potential of proapoptotic receptor agonistsSenescence-dependent impact of anti-RAGE antibody on endotoxemic liver failureThe promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.Monoclonal antibodies in the treatment of pancreatic cancer.TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.Apoptosis pathways and their therapeutic exploitation in pancreatic cancer.X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists.Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy.Activity-based probes: discovering new biology and new drug targets.TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family.TRAIL-based therapy in pediatric bone tumors: how to overcome resistance.Proteomic tools for the characterization of cell death mechanisms in drug discovery.
P2860
Q26768160-36117D06-AE46-4E74-8749-133FC93992B0Q27024422-EEC5B350-49F8-4738-AB94-839CBE8E9064Q27676800-9DE46FB1-19C8-4A2B-AC20-F3A7DFA343E4Q27853200-791D2D11-8E05-47FB-B475-CC00EDD29766Q28548165-262B99B6-F3CD-41A2-AD04-AEE173D178A4Q28749299-8F0D4DD9-62F7-4BF2-AB4B-FA949F8788C7Q33726537-992B553F-1C22-4EAD-A1F1-2590E280C6B8Q33906524-EB24EA09-DD39-4FCF-970E-92DD12A3967FQ34060387-3C00EAB6-CD7D-4D33-8D1B-1AD2B35DA537Q34219368-6300AF23-0A69-485F-979B-82BB2C7FC40CQ34334395-0B176A9C-BD8F-4164-B9F8-D133DEDABB3CQ34988055-63729400-6758-45BB-A25A-4E9EE95D2DACQ35218738-345EC57B-8BA5-4D98-85BC-6DEE15A009D6Q35381670-4E0D821A-623A-4AA8-8233-4832ECC021C2Q35600638-5471A8E6-3152-432B-8221-E721398F43AFQ35705510-7BAC405F-EC1C-49BC-9544-02663CE5F6E6Q35936863-53CD03A3-01A0-4A0A-942A-08924DAF18CCQ36070101-CB9711FF-F333-4EA6-B5C5-DC3FDC00B666Q36174910-37D84934-C748-41DC-8660-984A1C36955CQ36342896-69498D26-C153-4D23-8445-D7CA0CBC75F4Q36347307-27BDBC82-EAB1-4A39-893F-38BA12AC9EC2Q36580632-3FFEA1B2-A41C-4AF5-BA90-83D39702A19EQ37003894-76142DEA-4961-4924-892F-E079B635673AQ37012681-79A53FC6-8039-4879-A4A7-152C06C5E278Q37021699-394DE833-4BAC-4911-B750-3D2616D96595Q37024543-89885C69-9BAC-4FE7-A2CD-9B379180C99DQ37061007-54994123-9DBC-418B-BE6A-29702D4D955CQ37181734-C90A8C50-8C69-46AF-B12C-B0ADD0D92FA5Q37300540-F9933ED3-A60A-4371-AD6D-50A56887ED7AQ37302737-5E0866B4-C9CF-451A-AAB5-B56F64FC134BQ37355568-A23EDE06-251B-4D42-B1A6-5B48EBF44EF1Q37440765-3C27FE65-EB25-4E1B-AD97-E0743966FB26Q37453523-51DFE28A-9EE4-456E-9486-7F2503298279Q37454149-429CBA95-0FFF-43BD-BC2A-8ADEE90FB035Q37621564-BB48CFDA-1478-49B1-B1C9-601E15B3CD23Q37795611-D5D6ABD3-2EEB-4811-8C6F-05160E22F351Q37972139-C182F7C2-9EB9-46F1-BEAF-11D168678483Q38098380-04050F1B-EAF4-4868-A6A3-C4212945BE99Q38352891-BDED52A7-0149-448C-97FA-BFF6B0D3B6D9Q38364625-46544738-0C3F-4C17-AF4A-4AB2C262F5F8
P2860
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Structural and functional anal ...... the proapoptotic receptor DR5
@ast
Structural and functional anal ...... the proapoptotic receptor DR5
@en
Structural and functional anal ...... the proapoptotic receptor DR5
@nl
type
label
Structural and functional anal ...... the proapoptotic receptor DR5
@ast
Structural and functional anal ...... the proapoptotic receptor DR5
@en
Structural and functional anal ...... the proapoptotic receptor DR5
@nl
prefLabel
Structural and functional anal ...... the proapoptotic receptor DR5
@ast
Structural and functional anal ...... the proapoptotic receptor DR5
@en
Structural and functional anal ...... the proapoptotic receptor DR5
@nl
P2093
P2860
P3181
P356
P1476
Structural and functional anal ...... the proapoptotic receptor DR5
@en
P2093
A Ashkenazi
D Lawrence
P2860
P2888
P304
P3181
P356
10.1038/SJ.CDD.4402306
P577
2008-04-01T00:00:00Z
P5875
P6179
1019980757